Modifier genes and variation in cystic fibrosis by Drumm, Mitchell L
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator; HLA = human leukocyte antigen; MBL = mannose binding
lectin; NO = nitric oxide; TGF-b1 = transforming growth factor-b1; TNF-a = tumor necrosis factor-a.
Available online http://respiratory-research.com/content/2/3/125
Introduction
Rozmahel et al [1] reported, in 1996, that the lethality
associated with a knockout allele of the murine cystic
fibrosis transmembrane conductance regulator (CFTR)
could be modified by different strain backgrounds. They
genetically mapped a locus conferring the modifying
effect to chromosome 7. Because the predominant mani-
festation of disrupting CFTR in the mouse is intestinal
obstruction, a feature of cystic fibrosis (CF) in humans, a
region of the human genome on chromosome 19 corre-
sponding to the mouse locus was tracked in siblings with
CF. Zielenski et al [2] thus found the occurrence or
absence of meconium ileus, a perinatal form of intestinal
obstruction, coincided with haplotypes of chromosome
19 inherited by the siblings. This coincidence implied that
the gene conferring resistance or susceptibility to intesti-
nal obstruction in mice is also polymorphic in humans,
and that those polymorphisms have a similar effect on CF
patients to that which strain variants of these genes have
on CF mice.
Whereas the identity of the gene, or genes, responsible
for this phenomenon has not yet been determined, this
study illustrates several important points. Firstly, it demon-
strates that some of the clinical variation between CF
patients is genetic, but conferred by genes other than that
for CFTR. It importantly also indicates that relatively
common genetic variation, with little or no overt pheno-
typic effect on the general population, can have a signifi-
cant effect in the context of CF.
This is an important precedent for CF, but the effect of
this particular locus seems restricted to the gut. CF,
however, involves multiple organs whose common feature
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is epithelium expressing CFTR, and most morbidity and
mortality is due to the complications in the respiratory
tract. Decreased mucociliary clearance, viscous secre-
tions and glandular plugging by these secretions, and
altered ion transport are all thought to contribute to the
milieu that allows colonization by opportunistic species of
bacteria, such as Staphylococcus aureus, Pseudomonas
aeruginosa  and Burkholderia cepacia. Associated with
the chronic infection is an overwhelming inflammatory
response that, together, lead to destruction of the airways.
Clinical and basic research regarding CF is consequently
focusing on the airways, but identifying effective sites for
intervention remains elusive (see [3]).
Searching for modifier genes of pulmonary disease is one
approach to identify therapeutic targets. The identification
of genes that impact on the severity of CF airway disease
also illuminates therapeutic targets, either the protein
product of the gene or the entire pathway in which it acts.
Phenotype: a critical consideration
A genetic approach can certainly be powerful, but not
without caveats. As in any genetic study, the keystone is
the phenotype. Without a robust, reliably measured or
scored phenotype, a genetic effect is difficult to resolve.
Therein lies the biggest hurdle for CF: What is a relevant,
variable phenoptype that can be accurately and reliably
measured or scored? As in the meconium ileus example,
one could classify a trait into categories, such as mild or
severe, and determine whether associations exist between
alleles of a particular gene and a phenotypic category.
Unfortunately, pulmonary disease in CF appears as a con-
tinuum of severities, unlike the present or absent pheno-
type of meconium ileus. There is also a temporal compo-
nent to the disease that confounds scoring [4]. Coloniza-
tion of the lungs by bacteria, for instance, is a consistent
feature of CF. Virtually all patients become colonized at
some point, although some acquire infection early in life
and some quite late. Therefore, if one wishes to use micro-
biology as a phenotype influenced by a modifier gene,
scoring simply by whether a patient is colonized is likely to
be inadequate. It would rather be more differentiating to
use criteria such as age at which a patient becomes colo-
nized, bacterial species, and so on. Pulmonary function
similarly declines in all patients, but the profile of decline
varies from patient to patient [4,5], with the greatest differ-
entiation obvious at older ages. This creates an inherent
difficulty in using pulmonary severity as a phenotype.
Patients are of all ages but, at the ages for which the
greatest resolution of severity is possible (ie late teens and
older), many of the severely affected patients are no
longer alive. Many studies comparing pulmonary severity
are therefore limited to patients’ latest pulmonary function
measurements.
The most relevant clinical phenotype is survival, but the
number of potential contributing factors (genetic and non-
genetic) is great and may dilute each other in an analysis.
It is therefore desirable to look at more specific traits that
convincingly contribute to the pathophysiology of the
disease. From the basic defect, genes that act on CFTR
gene expression, protein processing, protein turnover or
CFTR activity could all impact on disease. In the airway,
genes modifying the downstream effects of CFTR muta-
tions, such as infection susceptibility, impaired mucociliary
clearance, enhanced inflammatory response, and remodel-
ing of the airways (fibrosis), could all influence the disease
course (see Fig. 1). There are other conceptual considera-
tions as well. A CF modifier, for instance, may only modify
in a CF context, as appears to be the case for the meco-
nium ileus modifier. The modifier may alternatively modify a
trait in healthy and CF-affected individuals, but the clinical
significance of the effect is greater or exclusive to CF.
Candidate gene examples
The presented considerations bear on the choice of
approach. Garred et al [6], for example, reasoned that
genes involved in innate defense against bacteria outside
CF might also be relevant in the context of CF. They exam-
ined CF patients for alleles of the mannose-binding lectin
(MBL) gene associated with reduced serum levels of
MBL. MBL is a member of the collectin family of proteins,
participating in innate defense against bacteria [6]. This
and a similar study [7] showed that pulmonary function
was significantly lower in patients carrying low-expression
MBL alleles. Survival predictions based on pulmonary
function profiles indicate that patients with the low-expres-
sion MBL alleles will have a shorter lifespan than those
with high-expression alleles [6].
Figure 1
Potential sites for the effects of CF airway modifiers. Genes that affect
the expression of CFTR, processing of the CFTR protein, or activity of
ion channels in the epithelium, as well as control of mucus production
and mucociliary clearance (left), could all have an impact on the
sequence of events in the CF lung. Genes that influence the
consequences of the defects at the epithelium, such as infection,
chemotactic signals of inflammation, and tissue remodeling, would also
be likely to modify clinical manifestations of the disease.c
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Genes of the major histocompatibility complex play a role
in immune defense and allergic responses. Aron et al [8]
consequently looked for associations between class II
human leukocyte antigens (HLA) and indices of pulmonary
disease in CF. The HLA gene alleles showed no associa-
tion with most traits, but presence of the DR7 allele did
show some correlation with P aeruginosa colonization.
Another player in the host defense system is nitric oxide
(NO). Expired NO levels are reduced in CF. NO may have
some antimicrobial role against P aeruginosa so this
decrease may have serious functional consequences
[9,10]. Expression of the NOS2 gene is downregulated in
CF airway epithelial cells [9,10], perhaps accounting for
the reduced NO levels in CF. However, another nitric
oxide synthase gene, NOS1, shows significant airway
expression and its alleles were evaluated for association
with pulmonary disease. Grasemann et al [11] found that
an intronic trinucleotide repeat in the NOS1 gene not only
associated with differences in exhaled NO (greater repeat
number is associated with lower NO levels), but that colo-
nization by P aeruginosa and Aspergillus fumigatus also
associated with the high repeat number.
Associated with infection is inflammation, a process
thought to contribute significantly to the destruction of the
lung (reviewed in [3]). Polymorphisms in genes involved in
infection and inflammation are numerous (for reviews, see
[12–14]), which prompted Hull and Thomson [15] to look
at several genes that are probably important in CF airway
inflammation, namely those encoding the cytokine tumor
necrosis factor-a (TNF-a) and the anti-oxidant glutathione-
S-transferase-M1 (GST-M1). While no association was
found for GST-M1 alleles, a high-expression TNF-a allele
was found to be associated with lower body mass index
and pulmonary function. The gene for transforming growth
factor-b1 (TGF-b1), a cytokine with many effects (profi-
brotic [16], anti-inflammatory [17]), was similarly studied
with regard to its effect on CF pulmonary function.
Patients carrying an allele associated with high expression
of TGF-b1 had a more rapid decline in pulmonary function
than patients carrying low-expression alleles, from which
the authors implied that the profibrotic function of TGF-b1
dominates its effect on the CF lung [18].
The CF airway modifiers examined thus far have consisted
of candidate genes chosen because of their suspected
role in CF pathophysiology and because they have identi-
fied polymorphisms. The gastrointestinal manifestations of
CF, however, show that other approaches should also be
pursued. In addition to the meconium ileus modifier identi-
fied by traditional genetics, pathways that influence mucin
expression are predicted to be CF gut modifiers based on
a transgenic mouse model. Parmley and Gendler [19]
found that CF mice on a background in which the Muc1
gene is knocked out did not experience the intestinal
obstruction characteristic of CF animals and so, while not
identified by polymorphisms, the Muc1 gene clearly modi-
fies the CF phenotype.
Conclusion
The literature is full of modifier-type studies for many dis-
eases, but this is just the beginning. The genome
sequencing efforts are identifying thousands of polymor-
phisms (see [20]), thereby providing the potential to study,
in the near future, virtually any gene of suspected interest.
These studies will provide associations but, because of
the number of comparisons that will be possible, chance
associations are a certainty. Results must therefore be
interpreted with caution. It must be remembered that a
candidate gene approach is one of association, not cause
and effect. The opportunities are nonetheless exciting and
hold much promise toward our understanding of CF
pathophysiology and the potential to thwart it.
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